Marupuru Srujitha, Senapati Padmanav, Pathadka Swathi, Miraj Sonal Sekhar, Unnikrishnan Mazhuvancherry Kesavan, Manu Mohan K
Manipal University, Manipal College of Pharmaceutical Sciences, Department of Pharmacy Practice, Manipal, India.
Manipal University, Manipal College of Pharmaceutical Sciences, Department of Pharmacy Practice, Manipal, India.
Braz J Infect Dis. 2017 May-Jun;21(3):312-316. doi: 10.1016/j.bjid.2017.01.001. Epub 2017 Feb 13.
World Health Organization estimated that people with diabetes (DM) are at 2-3 times higher risk for tuberculosis (TB). Studies have shown that DM not only increases the risk of active TB, but also puts co-affected persons at increased risk of poor outcomes.
To determine the protective effect of metformin against TB in DM patients and also, to investigate the relationship between poor glycemic control and TB.
A case-control study was conducted over 8 months, where cases and controls were selected based on the inclusion and exclusion criteria of the study. The diabetics diagnosed with TB were selected as study group (SG=152) and without TB were as control group (CG=299). Exposure status of metformin in both groups were analyzed.
The mean (SD) age of both CG and SG were 55.54±11.82 and 52.80±11.75, respectively. Majority of the subjects in the study were males. The mean hospital stay of SG and CG were 7 days and 6 days, respectively. Poor glycemic control (HbA1c>8) observed in SG (51.7%) vs CG (31.4%). HbA1c value <7 is associated protective factor for TB occurrence [OR=0.52 (95% CI 0.29-0.93)]. The protective effect of metformin against TB was 3.9-fold in diabetics (OR=0.256, 0.16-0.40).
Poor glycemic control among diabetics is a risk factor for TB occurrence. The result shows metformin use is a protective agent against TB infection in diabetics. Hence, incorporation of metformin into standard clinical care would offer a therapeutic option for the prevention of TB.
世界卫生组织估计,糖尿病患者患结核病的风险高出2至3倍。研究表明,糖尿病不仅会增加活动性结核病的风险,还会使合并感染的患者出现不良后果的风险增加。
确定二甲双胍对糖尿病患者结核病的保护作用,并研究血糖控制不佳与结核病之间的关系。
进行了一项为期8个月的病例对照研究,根据研究的纳入和排除标准选择病例和对照。将被诊断患有结核病的糖尿病患者选为研究组(SG = 152),未患结核病的糖尿病患者选为对照组(CG = 299)。分析两组中二甲双胍的暴露情况。
CG组和SG组的平均(标准差)年龄分别为55.54±11.82岁和52.80±11.75岁。研究中的大多数受试者为男性。SG组和CG组的平均住院天数分别为7天和6天。SG组(51.7%)的血糖控制不佳(糖化血红蛋白>8)情况高于CG组(31.4%)。糖化血红蛋白值<7是结核病发生的相关保护因素[比值比=0.52(95%置信区间0.29 - 0.93)]。二甲双胍对糖尿病患者结核病的保护作用为3.9倍(比值比=0.256,0.16 - 0.40)。
糖尿病患者血糖控制不佳是结核病发生的危险因素。结果表明,使用二甲双胍是糖尿病患者预防结核病感染的保护剂。因此,将二甲双胍纳入标准临床护理可为预防结核病提供一种治疗选择。